Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have received a consensus rating of “Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $43.17.

ORKA has been the topic of several recent analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, December 20th. Finally, Stifel Nicolaus assumed coverage on Oruka Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective on the stock.

Oruka Therapeutics Stock Performance

ORKA stock opened at $11.44 on Tuesday. Oruka Therapeutics has a twelve month low of $11.32 and a twelve month high of $53.88. The stock has a market capitalization of $400.40 million, a price-to-earnings ratio of -1.83 and a beta of 0.81. The stock has a fifty day simple moving average of $19.10.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. bought a new stake in Oruka Therapeutics during the 4th quarter valued at $144,000. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth $343,000. The Manufacturers Life Insurance Company bought a new stake in Oruka Therapeutics during the third quarter valued at about $1,037,000. Wellington Management Group LLP purchased a new position in Oruka Therapeutics in the third quarter valued at about $2,013,000. Finally, Janus Henderson Group PLC bought a new position in Oruka Therapeutics in the third quarter worth about $5,840,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.